NASH and Specialty Biotech in 13Fs: MDGL, ASND, ARGX, KRYS

Specialty biotech — companies focused on rare diseases, novel therapeutic mechanisms, and late-stage clinical programs with binary catalysts — appears in a small but important set of US 13F filings at extreme concentrations. Paulson & Co. holds Madrigal Pharmaceuticals (MDGL) at 30.48% portfolio. Avoro Capital Advisors holds MDGL at 10.35% plus Ascendis Pharma (ASND) at 10.72%, Argenx (ARGX) at 8.18%, and Krystal Biotech (KRYS) at 7.00%. Smaller biotech-specialist funds and crossover venture investors show similar concentration patterns. Reading these positions requires understanding the specialty-biotech category — what these companies do, why active managers concentrate in them, and what to watch for catalysts.

What specialty biotech actually is

The 'specialty biotech' category typically includes:

• Rare-disease specialists. Companies developing therapies for diseases affecting fewer than 200,000 US patients. Regulatory incentives (orphan drug designation, pediatric vouchers) plus pricing-power dynamics make these commercially viable despite small patient populations. Examples: BioMarin, Vertex (which has expanded beyond), Ascendis Pharma, Krystal Biotech, Ionis Pharmaceuticals.
• Novel mechanism platforms. Companies whose drug-discovery platform represents a distinct technological approach. Examples: Argenx (FcRn antagonism), Kymera Therapeutics (protein degradation), Arrowhead Pharmaceuticals (RNAi), Avidity Biosciences (antibody-oligonucleotide conjugates), Structure Therapeutics (oral GLP-1).
• First-in-class commercial assets. Companies that have achieved FDA approval for the first therapy in a disease category. Examples: Madrigal Pharmaceuticals (first oral NASH therapy), Ascendis Pharma (Skytrofa for achondroplasia, Yorvipath for hypoparathyroidism).
• Late-stage clinical programs with binary catalysts. Companies with Phase 3 readouts approaching that determine commercial viability.

Why specialty biotech produces concentrated 13F bets

Three structural drivers:

1. Binary catalysts produce asymmetric returns. A Phase 3 readout or FDA approval can double the stock; a failure can halve it. Position sizing reflects conviction in the underlying scientific and commercial thesis.
2. Small market caps allow meaningful position sizing. Many specialty biotech names are sub-$10 billion market cap. A $1 billion position represents 10%+ ownership — too big for diversified active managers but appropriate for specialist funds with smaller AUM.
3. Specialist research is required. Biotech investing requires medical-and-scientific research depth that most diversified active managers don't have in-house. Specialist firms (Avoro, Baker Bros, RTW Investments, Perceptive Advisors, Deep Track Capital, Bain Capital Life Sciences) compete in this category.

The major specialty-biotech 13F filers

• Avoro Capital Advisors — $10.17B AUM, top 10 entirely biotech (UTHR, ASND, MDGL, ARGX, KRYS, ARWR, KYMR, GPCR, RNA, CNTA). Cleanest pure-play biotech specialist.
• Baker Bros. Advisors — Long-running biotech-only investor with concentrated positions.
• Perceptive Advisors — Biotech specialist with crossover venture + public-equity strategies.
• RTW Investments — Multi-fund biotech specialist.
• Deep Track Capital — Biotech specialist.
• Bain Capital Life Sciences — Multi-strategy biotech-and-life-sciences investor.
• Paulson & Co. — Not biotech-only but holds Madrigal at 30.48% portfolio as the largest single position.

How to read specialty biotech concentration

Three rules:

Rule 1: Read the position weight against the catalyst calendar

Concentrated specialty-biotech positions usually align with specific clinical or commercial catalysts. Madrigal's commercial uptake post-FDA approval (March 2024) drove Paulson's 30% concentration. Avoro's combined NASH (MDGL) + rare disease (ASND, KRYS) + autoimmune (ARGX) + protein-degradation (KYMR) + RNAi (ARWR) positions each reflect specific Phase 3 readouts or commercial-launch trajectories.

Rule 2: Watch for catalyst-driven exits

Specialty-biotech positions can compress quickly post-catalyst:

• Positive Phase 3 readout: Position typically holds or expands modestly; partial profit-taking is common.
• Negative Phase 3 readout: Position drops sharply; specialist managers often trim aggressively to redeploy capital into other names.
• Acquisition rumor: Specialists sometimes accumulate ahead of expected M&A; the position trims at takeout premium.

Rule 3: Cross-check against insider activity and biotech-specialist consensus

Specialty-biotech investments work best when multiple specialist managers converge on the same names. When Avoro, RTW, Perceptive, and Baker Bros all hold a name at top-10 concentration, the cross-fund consensus is structural. When only one specialist holds it, the conviction is idiosyncratic and the binary risk is higher.

The current consensus names

• Madrigal Pharmaceuticals (MDGL): NASH commercial-launch story. Paulson + Avoro + multiple other specialist managers concentrate at meaningful weights.
• Ascendis Pharma (ASND): Rare-disease (achondroplasia, hypoparathyroidism) franchise with TransCon platform extension.
• Argenx (ARGX): Vyvgart franchise in autoimmune neuromuscular disease.
• Krystal Biotech (KRYS): Vyjuvek topical gene therapy.

These four names appear together in multiple specialist 13Fs at top-10 concentrations. The cross-fund consensus is the structural underpinning of the institutional view on the specialty biotech category.

What to track

1. Quarterly clinical and commercial readouts. Each top-tier specialty biotech has multiple readouts annually. Tracking them produces the underlying catalyst pipeline.
2. Specialist fund flow. Position changes at Avoro, RTW, Perceptive, Baker Bros, Bain Life Sciences signal sector-rotation views.
3. Big-pharma M&A. Specialty-biotech leaders are frequent takeout candidates. Watch the M&A calendar.

For real-time tracking of specialty-biotech 13F activity, see the institutional signals feed. For related reading techniques on concentrated active manager 13Fs, see our explainer hub.